Despite extensive PI3K/AKT/mTOR inhibitor development efforts, only a limited number of compounds have been approved by the US Food and Drug Administration (FDA) (Table 1). The mechanistic target of ...
Osteoarthritis (OA) is a common degenerative disease characterized by chondrocyte death and extracellular matrix (ECM) degradation, but the present OA treatments are only symptomatic and not ...
A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results